anti-CD19 CAR T-cell therapy (Loyola University of Chicago)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameanti-CD19 CAR T-cell therapy (Loyola University of Chicago)

Drug Alias NameCD19 CAR T-cell therapy (Loyola University of Chicago)CD19-CD34 CAR transduced T cell therapy (Loyola University of Chicago)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionB-lymphocyte antigen CD19 modulators

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma, B-CellPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesLoyola University

China Registration ClassN/A

Develop Information

Active CompaniesLoyola University

Inactive CompaniesN/A

Active IndicationsLymphoma, B-CellPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A